{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:49:30Z","timestamp":1761630570817},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,1,27]],"date-time":"2011-01-27T00:00:00Z","timestamp":1296086400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1007\/s00393-010-0687-0","type":"journal-article","created":{"date-parts":[[2011,1,25]],"date-time":"2011-01-25T14:29:40Z","timestamp":1295965780000},"page":"108-113","source":"Crossref","is-referenced-by-count":10,"title":["Methotrexat-Toxizit\u00e4t"],"prefix":"10.1007","volume":"70","author":[{"given":"G.","family":"Key\u00dfer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,1,27]]},"reference":[{"key":"687_CR1","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/rheumatology\/37.10.1060","volume":"37","author":"Menninger","year":"1998","unstructured":"Menninger H, Herborn G, Sander O et al (1998) A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis. Br J Rheumatol 37:1060\u20131068","journal-title":"Br J Rheumatol"},{"key":"687_CR2","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/ard.2008.093690","volume":"68","author":"Salliot","year":"2009","unstructured":"Salliot C, van der Heijde D (2009) Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 68:1100\u20131104","journal-title":"Ann Rheum Dis"},{"key":"687_CR3","first-page":"261","volume":"29","author":"Papadopoulos","year":"2002","unstructured":"Papadopoulos NG, Alamanos Y, Papadopoulos IA et al (2002) Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study. J Rheumatol 29:261\u2013266","journal-title":"J Rheumatol"},{"key":"687_CR4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s003930050181","volume":"58","author":"Keysser","year":"1999","unstructured":"Keysser M, Keysser G, Keysser C (1999) Long-term application of disease modifying antirheumatic drugs (DMARD). A single-center, observational study of 1681 patients with rheumatoid arthritis (RA). Z Rheumatol 58:267\u2013276","journal-title":"Z Rheumatol"},{"key":"687_CR5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/ard.62.4.291","volume":"62","author":"Gerards","year":"2003","unstructured":"Gerards AH, Landewe RB, Prins AP et al (2003) Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Ann Rheum Dis 62:291\u2013296","journal-title":"Ann Rheum Dis"},{"key":"687_CR6","doi-asserted-by":"crossref","unstructured":"Choy EH, Smith C, Dore CJ, Scott DL (2005) A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology (Oxford) 44:1414\u20131421","DOI":"10.1093\/rheumatology\/kei031"},{"key":"687_CR7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/PL00006851","volume":"17","author":"Elkayam","year":"1997","unstructured":"Elkayam O, Yaron M, Zhukovsky G et al (1997) Toxicity profile of dual methotrexate combinations with gold, hydroxychloroquine, sulphasalazine and minocycline in rheumatoid arthritis patients. Rheumatol Int 17:49\u201353","journal-title":"Rheumatol Int"},{"key":"687_CR8","first-page":"1485","volume":"25","author":"Rau","year":"1998","unstructured":"Rau R, Schleusser B, Herborn G, Karger T (1998) Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy. J Rheumatol 25:1485\u20131492","journal-title":"J Rheumatol"},{"key":"687_CR9","doi-asserted-by":"crossref","unstructured":"Amital H, Arnson Y, Chodick G, Shalev V (2009) Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate. Rheumatology (Oxford) 48:1107\u20131110","DOI":"10.1093\/rheumatology\/kep176"},{"key":"687_CR10","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00002512-200825100-00007","volume":"25","author":"Bernatsky","year":"2008","unstructured":"Bernatsky S, Ehrmann FD (2008) Discontinuation of methotrexate therapy in older patients with newly diagnosed rheumatoid arthritis: analysis of administrative health databases in Quebec, Canada. Drugs Aging 25:879\u2013884","journal-title":"Drugs Aging"},{"key":"687_CR11","first-page":"1727","volume":"31","author":"Kent","year":"2004","unstructured":"Kent PD, Luthra HS, Michet C Jr (2004) Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis. J Rheumatol 31:1727\u20131731","journal-title":"J Rheumatol"},{"key":"687_CR12","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00228-008-0521-7","volume":"64","author":"Bohanec","year":"2008","unstructured":"Bohanec GP, Logar D, Lestan B, Dolzan V (2008) Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur J Clin Pharmacol 64:1057\u20131068","journal-title":"Eur J Clin Pharmacol"},{"key":"687_CR13","first-page":"572","volume":"35","author":"Ranganathan","year":"2008","unstructured":"Ranganathan P, Culverhouse R, Marsh S et al (2008) Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 35:572\u2013579","journal-title":"J Rheumatol"},{"key":"687_CR14","first-page":"521","volume":"124","author":"Aggarwal","year":"2006","unstructured":"Aggarwal P, Naik S, Mishra KP et al (2006) Correlation between methotrexate efficacy & toxicity with C677T polymorphism of the methylenetetrahydrofolate gene in rheumatoid arthritis patients on folate supplementation. Indian J Med Res 124:521\u2013526","journal-title":"Indian J Med Res"},{"key":"687_CR15","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.3899\/jrheum.091427","volume":"37","author":"Tukova","year":"2010","unstructured":"Tukova J, Chladek J, Hroch M et al (2010) 677TT genotype is associated with elevated risk of methotrexate (MTX) toxicity in juvenile idiopathic arthritis: treatment outcome, erythrocyte concentrations of MTX and folates, and MTHFR polymorphisms. J Rheumatol 37:2180\u20132186","journal-title":"J Rheumatol"},{"key":"687_CR16","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.3899\/jrheum.091311","volume":"37","author":"Chandran","year":"2010","unstructured":"Chandran V, Siannis F, Rahman P et al (2010) Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis. J Rheumatol 37:1508\u20131512","journal-title":"J Rheumatol"},{"key":"687_CR17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/11531070-000000000-00000","volume":"30","author":"Lee","year":"2010","unstructured":"Lee YH, Song GG (2010) Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis. Clin Drug Investig 30:101\u2013108","journal-title":"Clin Drug Investig"},{"key":"687_CR18","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3899\/jrheum.080576","volume":"36","author":"Fisher","year":"2009","unstructured":"Fisher MC, Cronstein BN (2009) Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J Rheumatol 36:539\u2013545","journal-title":"J Rheumatol"},{"key":"687_CR19","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1002\/art.22129","volume":"54","author":"Dervieux","year":"2006","unstructured":"Dervieux T, Greenstein N, Kremer J (2006) Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum 54:3095\u20133103","journal-title":"Arthritis Rheum"},{"key":"687_CR20","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1002\/art.22032","volume":"54","author":"Wessels","year":"2006","unstructured":"Wessels JA, Kooloos WM, De JR et al (2006) Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 54:2830\u20132839","journal-title":"Arthritis Rheum"},{"key":"687_CR21","doi-asserted-by":"crossref","unstructured":"Hider SL, Thomson W, Mack LF et al (2008) Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX. Rheumatology (Oxford) 47:1156\u20131159","DOI":"10.1093\/rheumatology\/ken182"},{"key":"687_CR22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2217\/pgs.09.139","volume":"11","author":"Kooloos","year":"2010","unstructured":"Kooloos WM, Wessels JA, ST van der et al (2010) Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Pharmacogenomics 11:163\u2013175","journal-title":"Pharmacogenomics"},{"key":"687_CR23","unstructured":"Rau R (2007) Nebenwirkungen. In: Rau R (Hrsg) Das Methotrexat-Buch \u2013 Aktuelle Therapiekonzepte in der Rheumatologie und Dermatologie, 1. Aufl. Uni-Med, Bremen, S 55\u201363"},{"key":"687_CR24","first-page":"36","volume":"25","author":"Ortiz","year":"1998","unstructured":"Ortiz Z, Shea B, Suarez-Almazor ME et al (1998) The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol 25:36\u201343","journal-title":"J Rheumatol"},{"key":"687_CR25","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ard.2008.092668","volume":"68","author":"Visser","year":"2009","unstructured":"Visser K, van der Heijde D (2009) Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 68:1094\u20131099","journal-title":"Ann Rheum Dis"},{"key":"687_CR26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.23144","volume":"58","author":"Braun","year":"2008","unstructured":"Braun J, Kastner P, Flaxenberg P et al (2008) Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 58:73\u201381","journal-title":"Arthritis Rheum"},{"key":"687_CR27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00044011-200626020-00001","volume":"26","author":"Tilling","year":"2006","unstructured":"Tilling L, Townsend S, David J (2006) Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investig 26:55\u201362","journal-title":"Clin Drug Investig"},{"key":"687_CR28","first-page":"801","volume":"85","author":"Hopwood","year":"1977","unstructured":"Hopwood D, Nyfors A (1977) Liver ultrastructure in psoriatics related to methotrexate therapy. 2. Findings in bile ducts from 11 methotrexate treated psoriatics and 2 controls. Acta Pathol Microbiol Scand A 85:801\u2013811","journal-title":"Acta Pathol Microbiol Scand A"},{"key":"687_CR29","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.3899\/jrheum.090482","volume":"36","author":"Kocharla","year":"2009","unstructured":"Kocharla L, Taylor J, Weiler T et al (2009) Monitoring methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol 36:2813\u20132818","journal-title":"J Rheumatol"},{"key":"687_CR30","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/ard.2008.106617","volume":"69","author":"Verstappen","year":"2010","unstructured":"Verstappen SM, Bakker MF, Heurkens AH et al (2010) Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. Ann Rheum Dis 69:1044\u20131048","journal-title":"Ann Rheum Dis"},{"key":"687_CR31","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1365-2036.2006.03047.x","volume":"24","author":"Berends","year":"2006","unstructured":"Berends MA, Snoek J, Jong EM de et al (2006) Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent. Aliment Pharmacol Ther 24:805\u2013811","journal-title":"Aliment Pharmacol Ther"},{"key":"687_CR32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/art.1780360307","volume":"36","author":"Walker","year":"1993","unstructured":"Walker AM, Funch D, Dreyer NA et al (1993) Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum 36:329\u2013335","journal-title":"Arthritis Rheum"},{"key":"687_CR33","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/ard.62.5.423","volume":"62","author":"Hoekstra","year":"2003","unstructured":"Hoekstra M, Ede AE van, Haagsma CJ et al (2003) Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 62:423\u2013426","journal-title":"Ann Rheum Dis"},{"key":"687_CR34","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/art.1780401016","volume":"40","author":"Kremer","year":"1997","unstructured":"Kremer JM, Alarcon GS, Weinblatt ME et al (1997) Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 40:1829\u20131837","journal-title":"Arthritis Rheum"},{"key":"687_CR35","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1517\/14740338.4.4.723","volume":"4","author":"Lateef","year":"2005","unstructured":"Lateef O, Shakoor N, Balk RA (2005) Methotrexate pulmonary toxicity. Expert Opin Drug Saf 4:723\u2013730","journal-title":"Expert Opin Drug Saf"},{"key":"687_CR36","first-page":"727","volume":"19","author":"Belzunegui","year":"2001","unstructured":"Belzunegui J, Intxausti JJ, De D Jr et al (2001) Absence of pulmonary fibrosis in patients with psoriatic arthritis treated with weekly low-dose methotrexate. Clin Exp Rheumatol 19:727\u2013730","journal-title":"Clin Exp Rheumatol"},{"key":"687_CR37","doi-asserted-by":"crossref","unstructured":"Dawson JK, Graham DR, Desmond J et al (2002) Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology (Oxford) 41:262\u2013267","DOI":"10.1093\/rheumatology\/41.3.262"},{"key":"687_CR38","doi-asserted-by":"crossref","unstructured":"Karie S, Gandjbakhch F, Janus N et al (2008) Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology (Oxford) 47:350\u2013354","DOI":"10.1093\/rheumatology\/kem370"},{"key":"687_CR39","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1445-5994.2009.02059.x","volume":"40","author":"White","year":"2010","unstructured":"White DH, Chapman PT, O\u2019Donnell JL et al (2010) Lack of association between elevated mean red cell volume and haematological toxicity in patients receiving long-term methotrexate for rheumatoid arthritis. Intern Med J 40:561\u2013565","journal-title":"Intern Med J"},{"key":"687_CR40","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/ard.2004.023408","volume":"64","author":"Yazici","year":"2005","unstructured":"Yazici Y, Sokka T, Kautiainen H et al (2005) Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 64:207\u2013211","journal-title":"Ann Rheum Dis"},{"key":"687_CR41","doi-asserted-by":"crossref","unstructured":"Lim AY, Gaffney K, Scott DG (2005) Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years. Rheumatology (Oxford) 44:1051\u20131055","DOI":"10.1093\/rheumatology\/keh685"},{"key":"687_CR42","first-page":"2374","volume":"31","author":"Hornung","year":"2004","unstructured":"Hornung N, Ellingsen T, Stengaard-Pedersen K, Poulsen JH (2004) Folate, homocysteine, and cobalamin status in patients with rheumatoid arthritis treated with methotrexate, and the effect of low dose folic acid supplement. J Rheumatol 31:2374\u20132381","journal-title":"J Rheumatol"},{"key":"687_CR43","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.tripleo.2004.08.020","volume":"100","author":"Kalantzis","year":"2005","unstructured":"Kalantzis A, Marshman Z, Falconer DT et al (2005) Oral effects of low-dose methotrexate treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100:52\u201362","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"687_CR44","first-page":"867","volume":"19","author":"Kerstens","year":"1992","unstructured":"Kerstens PJ, Boerbooms AM, Jeurissen ME et al (1992) Accelerated nodulosis during low dose methotrexate therapy for rheumatoid arthritis. An analysis of ten cases. J Rheumatol 19:867\u2013871","journal-title":"J Rheumatol"},{"key":"687_CR45","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.1780310915","volume":"31","author":"Segal","year":"1988","unstructured":"Segal R, Caspi D, Tishler M et al (1988) Accelerated nodulosis and vasculitis during methotrexate therapy for rheumatoid arthritis. Arthritis Rheum 31:1182\u20131185","journal-title":"Arthritis Rheum"},{"key":"687_CR46","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/ard.53.4.224","volume":"53","author":"Veen","year":"1994","unstructured":"Veen MJ van der, HA van der, Kruize AA, Bijlsma JW (1994) Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 53:224\u2013228","journal-title":"Ann Rheum Dis"},{"key":"687_CR47","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s10067-008-0888-y","volume":"27","author":"Pieringer","year":"2008","unstructured":"Pieringer H, Stuby U, Biesenbach G (2008) The place of methotrexate perioperatively in elective orthopedic surgeries in patients with rheumatoid arthritis. Clin Rheumatol 27:1217\u20131220","journal-title":"Clin Rheumatol"},{"key":"687_CR48","doi-asserted-by":"crossref","unstructured":"Kapetanovic MC, Saxne T, Sjoholm A et al (2006) Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 45:106\u2013111","DOI":"10.1093\/rheumatology\/kei193"},{"key":"687_CR49","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.clinthera.2009.08.009","volume":"31","author":"Roon","year":"2009","unstructured":"Roon EN van, Bemt PM van den, Jansen TL et al (2009) An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists. Clin Ther 31:1737\u20131746","journal-title":"Clin Ther"},{"key":"687_CR50","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3899\/jrheum.090153","volume":"37","author":"Bourre-Tessier","year":"2010","unstructured":"Bourre-Tessier J, Haraoui B (2010) Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J Rheumatol 37:1416\u20131421","journal-title":"J Rheumatol"},{"key":"687_CR51","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/art.20312","volume":"50","author":"Symmons","year":"2004","unstructured":"Symmons DP, Silman AJ (2004) Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer. Arthritis Rheum 50:1703\u20131706","journal-title":"Arthritis Rheum"},{"key":"687_CR52","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","volume":"54","author":"Baecklund","year":"2006","unstructured":"Baecklund E, Iliadou A, Askling J et al (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:692\u2013701","journal-title":"Arthritis Rheum"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-010-0687-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-010-0687-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-010-0687-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T03:46:27Z","timestamp":1559965587000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-010-0687-0"}},"subtitle":["Mythen und Fakten"],"short-title":[],"issued":{"date-parts":[[2011,1,27]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["687"],"URL":"https:\/\/doi.org\/10.1007\/s00393-010-0687-0","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,27]]}}}